"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 3 | 7 |
| 1996 | 6 | 1 | 7 |
| 1997 | 4 | 2 | 6 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 4 | 0 | 4 |
| 2001 | 3 | 3 | 6 |
| 2002 | 2 | 4 | 6 |
| 2003 | 8 | 2 | 10 |
| 2004 | 6 | 1 | 7 |
| 2005 | 3 | 4 | 7 |
| 2006 | 2 | 3 | 5 |
| 2007 | 3 | 2 | 5 |
| 2008 | 4 | 4 | 8 |
| 2009 | 4 | 4 | 8 |
| 2010 | 4 | 4 | 8 |
| 2011 | 3 | 6 | 9 |
| 2012 | 2 | 7 | 9 |
| 2013 | 1 | 9 | 10 |
| 2014 | 3 | 6 | 9 |
| 2015 | 2 | 3 | 5 |
| 2016 | 10 | 10 | 20 |
| 2017 | 0 | 10 | 10 |
| 2018 | 3 | 10 | 13 |
| 2019 | 5 | 5 | 10 |
| 2020 | 3 | 4 | 7 |
| 2021 | 3 | 5 | 8 |
| 2022 | 0 | 5 | 5 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 6 | 7 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers. Clin Cancer Res. 2025 Jan 17; 31(2):403-413.
-
ASO Author Reflections: Breast-Conserving Surgery After Neoadjuvant Systemic Therapy for Early-Stage Breast Cancer: Quantitative Biomarkers and Disparities in the Precision-Medicine Era. Ann Surg Oncol. 2024 Dec; 31(13):8904-8905.
-
Quantitative Biomarkers, Genomic Assays, and Demographics Associated with Breast-Conserving Surgery Following Neoadjuvant Therapy in Early-Stage, Hormone Receptor-Positive, HER-Negative Breast Cancer. Ann Surg Oncol. 2024 Dec; 31(13):8829-8842.
-
Glucocorticoid receptor-mediated oncogenic activity is dependent on breast cancer subtype. J Steroid Biochem Mol Biol. 2024 10; 243:106518.
-
Using genome and transcriptome data from African-ancestry female participants to identify putative breast cancer susceptibility genes. Nat Commun. 2024 May 02; 15(1):3718.
-
Expression- and splicing-based multi-tissue transcriptome-wide association studies identified multiple genes for breast cancer by estrogen-receptor status. Breast Cancer Res. 2024 Mar 21; 26(1):51.
-
Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Mar 01; 10(3):362-371.
-
Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 2024 Mar; 25(3):269-270.
-
Dynamic epi-transcriptomic landscape mapping with disease progression in estrogen receptor-positive breast cancer. Cancer Commun (Lond). 2023 05; 43(5):615-619.
-
Impact of Surgical Delay on Tumor Upstaging and Outcomes in Estrogen Receptor-Negative Ductal Carcinoma in Situ Patients. J Am Coll Surg. 2022 11 01; 235(5):788-798.